OCSIAL
28.2.2024 10:31:28 CET | Business Wire | Press release
OCSiAl, the global leader in the industrial synthesis of graphene nanotubes, announces the appointment of Peter Cuneo as Chairman of the Board of Directors.
As President and CEO of Marvel Entertainment, Mr. Cuneo orchestrated the legendary turnaround of a just-out-of-bankruptcy, struggling superhero franchise to an entertainment industry powerhouse, with the stock price rising from a low of $0.96 to $54 per share paid by Disney in 2009. Mr. Cuneo’s distinguished career also includes such roles as President and CEO of Remington Products, President of Black & Decker’s Security Hardware Group, and President of Bristol Myers Squibb pharmaceuticals group in Canada.
Mr. Cuneo brings to OCSiAl his wealth of strategic leadership experience and a proven track record of investment in many industries. Mr. Cuneo said, “I am thrilled to be joining OCSiAl which has the potential to become a world leader in nanotechnology.”
Konstantin Notman, CEO of OCSiAl, commented, “I am delighted to welcome Peter to the Board. His depth of experience and strategic leadership are exactly what OCSiAl needs as it looks forward to the next steps in its rise from a unicorn tech company to a global player.”
OCSiAl is dedicated to enhancing select properties of all base materials used by the global industry. The company develops universal nanotube solutions that allow its customers to add nanotubes to materials as part of standard manufacturing processes. Collaborating with customers and partners, OCSiAl creates new generations of nano-augmented materials and end products that have previously unattainable properties. These groundbreaking products set new market standards and will play a crucial role in accelerating the transition to a carbon-neutral future.
---
About OCSiAl
Headquartered in Luxembourg, OCSiAl is the world’s leading manufacturer of graphene nanotubes, also known as single wall carbon nanotubes. OCSiAl produces high-purity graphene nanotubes at industrial scale under the TUBALL™ brand name. Graphene nanotubes have potential applications across up to 50% of global materials markets. OCSiAl has developed and is marketing globally a wide range of nanotube products for electrochemical power sources and various polymers, and creates fundamentally new products based on them. The company’s sales force and distributor network cover more than 50 countries around the world.
https://ocsial.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228388902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rave Sues Apple in Five Countries Over App Store Removal7.5.2026 17:03:00 CEST | Press release
Alleges Antitrust Violations in U.S., Canada, Brazil, the Netherlands and Russia to Restore Access for Users and Defend Fair Competition for App DevelopersAlleges Apple Acted to Stop Rave from Competing with Apple’s Own Co-Viewing AppRave Launches Proprietary, AI-enabled Moderation System, a-eye.com, to Protect Users from Explicit Content Rave Inc. (“Rave” or the “Company”), the developer and operator of the Rave app, a cross-platform co-viewing “super app” with more than 225 million downloads, today announced that it has filed antitrust lawsuits against Apple in five countries: the United States, Canada, Brazil, the Netherlands and Russia. The lawsuits challenge Apple’s unilateral and anticompetitive decision to remove Rave from its App Store, thereby distorting competition, reducing consumer choice in co-viewing functionalities and increasing the costs to users of switching between iPhone and competing smartphone devices. Rave operates a social entertainment app that allows users in
emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide7.5.2026 17:00:00 CEST | Press release
First-time positioned vendor emnify recognized for its Completeness of Vision and Ability to Execute emnify, a global provider of cloud-native IoT connectivity solutions, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507642325/en/ emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. Get the report As a first-time recognized vendor, emnify believes this recognition reflects its forward-looking approach to IoT connectivity, building a platform designed to anticipate where enterprise needs are heading rather than replicating the connectivity models of the past. "We feel being named a Visionary in our first appearance in the Gartner® Magic Quadrant™ recognizes our deliberate strategy of the last decade: from owning our core netw
UAE Commits $49bn to Local Manufacturers7.5.2026 16:00:00 CEST | Press release
UAE to localize 5,000+ products in push for industrial sovereignty – Minister of Industry and Advanced Technology and ADNOC Group CEO Dr. Sultan Al Jaber The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical producti
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom